- Home
- BTE vs TARS Comparison
BTE vs TARS Comparison
Compare BTE & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | TARS |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTE | TARS |
|---|---|---|
| Price | $5.17 | $73.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $99.80 |
| AVG Volume (30 Days) | ★ 16.5M | 577.5K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $27.41 | $60.58 |
| Revenue Next Year | N/A | $28.32 |
| P/E Ratio | $18.43 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $2.18 | $53.89 |
| 52 Week High | $5.36 | $91.53 |
Technical Indicators
Market Signals| Indicator | BTE | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 69.36 | 47.82 |
| Support Level | $3.96 | $60.95 |
| Resistance Level | $5.17 | $79.10 |
| Average True Range (ATR) | 0.14 | 2.77 |
| MACD | 0.06 | -0.45 |
| Stochastic Oscillator | 98.23 | 40.24 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.